Lok Sabha Question No. 3145 (UNSTARRED), answered on 2019-12-06
Subject: Mission Madhumeha
Ministry: AYURVEDA,YOGA & NATUROPATHY,UNANI,SIDDHA AND HOMEOPATHY (AYUSH)
Asked by: Sanjay Jaiswal

## GOVERNMENT OF INDIA MINISTRY OF AYURVEDA, YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (AYUSH)

## LOK  SABHA UNSTARRED  QUESTION NO. 3145 TO BE ANSWERED ON 6 TH DECEMBER, 2019

## MISSION MADHUMEHA

## 3145. DR. SANJAY JAISWAL:

Will  the  Minister of AYURVEDA,  YOGA  AND  NATUROPATHY,  UNANI, SIDDHA AND HOMOEOPATHY (AYUSH) be pleased to state:

- (a) whether it is a fact that the India has second largest number of diabetic patients i and if so, the details thereof;
- (b)  whether  'Mission  Madhumeha'  has  been  able  to  address  this  challenge,  if  so,  the  details thereof; and
- (c) the steps being taken to popularize the 'BGR34' anti - diabetes medicine developed by CSIR;
- (d) whether the said medicine has therapeutic efficacy; and if so, the details thereof?

## ANSWER

## THE MINISTER OF STATE (IC) OF THE MINISTRY OF AYURVEDA, YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (SHRI SHRIPAD YESSO NAIK)

- (a): The  diabetic  population  in  the  country  is  close  to  hitting  the  alarming  mark  o million by 2025, which denotes that the country is expected to witness an increase of 266%
- (b): The Central of Research in Ayurveda Sciences (CCRAS), and au tonomous body under Ministry  of AYUSH has  been  engaged  in  extending  research  oriented  Ayurveda  based  on integrative health care services for the management of Madhumeha which is Diabetes Melli The following are the core activities
1. CCRAS  in collaboration with Directorate General of Health Services, Ministry Health  &  Family  Welfare  has  implemented  and  executed  a  programme  viz. Integration of AYUSH (Ayurveda) component with NPCDCS(National Programme for Prevention and Control of Ca ncer, Diabetes, Cardiovascular diseases & Stroke ) programme  in  the  identified  districts  of  3  states  viz.  Bhilwara  (Rajast Surendranagar (Gujarat) and Gaya (Bihar) to cater health care services and to r the burden of NCDs including Diabetes by co mbining the strength of Ayurveda and Yoga. The programme was launched during 2016 and continuing in 3 districts viz Bhilwara  (Rajasthan),  Surendranagar  (Gujarat)  and  Gaya  (Bihar). The  aforesaid

programme  is  now  successfully  functional  in  52  centres  (49  CH Cs  and  3  District Hospitals) of the all 3 identified districts, through AYUSH -NPCDCS Clinic/Lifestyle modification Clinics, established for prevention and management of selected NC by Ayurvedic intervention, Lifestyle modifications and Yoga Advice.

2. CCR AS  had  developed  the  AYUSH82  formulation  for  diabetes  through  scientific process  of  drug  development  and  commercialized  through  National  Research Development Corporation (NRDC) for wider public utility.
3. Generation of evidences on efficacy & safety of cla ssical Ayurveda formulation on Diabetes  Mellitus.  CCRAS  has  done  efficacy  and  safety  on  formulations  viz Nishamalki churna, Saptvinsti Gugullu, Yasad bhasm, Guduchi churna, Chandraprabha vati, Haridra churna anmd Gokshuradi Gugullu.
4. CCRAS has publishedthe documents viz. Protocol on Prevention and Management for  Diabetes  Mellitus  and  compendium  on  research  articles  on  Diabetes  Mellit which are made available in the public domain for benefit of practitioner's, physician and researchers

(c)  & (d):      Council  of  Scientific  and  Industrial  Research  (CSIR),  through  its  cons laboratories  namely  CSIR - Central  Institute  of  Medicinal  &  Aromatic  Plants  (CSIR - CIMAP), Lucknow; and CSIR - National Botanical Research Institute (CSIR - NBRI), Lucknow devel oped scientifically  validated  herbal  product  NBRMAP - D as  anti - diabetic  formulation  and  the knowhow for the product was licensed to M/s AIMIL Pharma Ltd., Delhi who are manufacturin and marketing it as BGR - 34, across the country.

M/s AIMIL Pharmaceuticals, the licensee carried out the clinical study of BGR - 34 and the trial was registered in clinical trial registry of India (Registration CTRI/2016/11/007476).  Further,  the  formulation  has  shown  therapeutic  efficacy  for  tre newly diag nosed type 2 diabetes, as found in independent clinical trials conducted at B Hindu University (BHU), Varanasi.

………………….